NVCR vs TMDX
NVCR: Novocure is an oncology company utilizing proprietary Tumor Treating Fields (TTFields) to disrupt cancer cell division through wearable, non-invasive electric field therapy. TMDX: TransMedics commercializes the only FDA-approved portable warm perfusion platform for multi-organ transplantation, replacing cold storage to dramatically increase donor organ utilization and post-transplant outcomes.
Side-by-side fundamentals
| Metric | NVCR | TMDX | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $15.69 | $80.21 | |
| Market cap as of 2026-08-08 | $1.8B | $2.8B | |
| P/E as of 2026-08-08 | n/a | 19.03 | |
| PEG as of 2026-08-08 | n/a | 0.21 | |
| Net margin as of 2026-08-08 | -21.3% | +22.7% | TMDX higher |
| Gross margin as of 2026-08-08 | +76.1% | +58.7% | NVCR higher |
| Operating margin as of 2026-08-08 | -22.1% | +12.2% | TMDX higher |
| ROE as of 2026-08-08 | -44.0% | +33.0% | TMDX higher |
| ROA as of 2026-08-08 | -15.8% | +12.3% | TMDX higher |
| Debt / equity as of 2026-08-08 | 0.58 | 1.66 | NVCR lower |
| Revenue growth (YoY) as of 2026-08-08 | +10.9% | +25.8% | TMDX higher |
| Revenue CAGR (3y) SEC XBRL | +6.8% | +86.4% | TMDX higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-08-08 | 1.01 | 1.97 | |
| 1-year return as of 2026-08-06 close | +37.8% | -32.5% | NVCR higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.